When presenting the data, Dr. Benjamin Solomon said first-line lorlatinib offers unprecedented improvement in outcomes for patients with advanced ALK+ non-small cell lung cancer. Read more
Dr. Natasha Leighl said the findings of PALOMA-3 show subcutaneous dosing offers other advantages, including reduced adverse events. Read more
Dr. Tony Mok said the results of the phase III KRYSTAL-12 trial reinforce adagrasib as an effective second-line treatment option for this patient population. Read more
Drs. Joelle Fathi and Matt Evision say cytisine more than doubles the chance of cessation and its expanding accessibility heralds a new era in the management of tobacco dependency. Read more
The European Commission has approved adjuvant alectinib for ALK+ early-stage NSCLC while the US FDA has granted priority review for osimertinib for unresectable stage III EGFR+ NSCLC. Read more
Primary results from the study, presented by Dr. Suresh Ramalingam, showed osimertinib offers a significant improvement in progression-free survival following chemoradiotherapy. Read more
As the first study to establish the role of immunotherapy in this setting, Dr. David R. Spigel says consolidation durvalumab will become the new standard of care for this population. Read more
Runner and patient advocate Angus Pratt says running three times a week may be the antithesis of what most people expect from a lung cancer patient, but not only is it possible, it is beneficial. Read more
With only 5% of patients stopping treatment due to treatment-related adverse events, lead author Yuankai Shi, MD, says glecirasib may help improve patient compliance with oral therapy. Read more
The first-in-class immunotherapy offers a new option for SCLC patients with disease progression on or after platinum-based chemotherapy. Read more